Core Viewpoint - ANI Pharmaceuticals, Inc. has received FDA approval for a new prefilled syringe format of Purified Cortrophin® Gel, enhancing patient administration convenience and reflecting the company's commitment to rare disease therapies [1][2]. Product Details - The new prefilled syringe will be available in two single-dose options: 40 USP units/0.5 mL and 80 USP units/mL, alongside existing vial formats of 5 mL and 1 mL [1]. - Cortrophin Gel is indicated for various conditions, including acute gouty arthritis, rheumatoid arthritis, systemic lupus erythematosus, and severe allergic and inflammatory conditions [4]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and commercializing innovative therapeutics, particularly in rare diseases, ophthalmology, rheumatology, nephrology, neurology, and pulmonology [6]. - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [6].

Financial Data and Key Metrics Changes - ANI Pharmaceuticals reported record fourth quarter and full year 2024 results, raising 2025 guidance for total revenues and adjusted non-GAAP EBITDA [10][11] - 2025 revenue is now expected to be between $756 million and $776 million, representing growth of 23% to 26% over 2024 [10][62] - Adjusted non-GAAP EBITDA for 2025 is projected to be between $190 million and $200 million, reflecting growth of 22% to 28% over 2024 [10][62] Business Line Data and Key Metrics Changes - Rare Disease was the primary growth driver in 2024, with Cortrophin Gel generating close to $200 million in sales [11][12] - Generics business achieved 12% revenue growth, marking the third consecutive year of double-digit growth [12] - Fourth quarter revenues for Rare Disease and Brands were $106.9 million, up 97% year-over-year, with Rare Disease revenues more than doubling to $87 million [53][55] Market Data and Key Metrics Changes - The overall ACTH market is expected to have grown about 25% to approximately $660 million in 2024 [38] - There are currently fewer than 5,000 patients on therapy for ILUVIEN and YUTIQ, with an estimated addressable patient population 6 to 10 times higher [89][113] - The demand for Cortrophin Gel increased across all targeted specialties, including neurology, rheumatology, nephrology, pulmonology, and ophthalmology [15][35] Company Strategy and Development Direction - The company aims to broaden its presence in the rare disease space, as evidenced by the acquisition of Alimera Sciences [12][11] - A core strategic rationale for the Alimera acquisition was to add synergistic assets and leverage existing infrastructure to unlock the potential of ILUVIEN and YUTIQ [17][51] - The company plans to continue investing in R&D and commercial initiatives to drive growth in its Rare Disease business [45][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for Cortrophin Gel and the overall ACTH market, despite current access issues for ILUVIEN and YUTIQ [89][114] - The company anticipates a typical Q4 to Q1 revenue drop for Cortrophin Gel, followed by strong sequential growth in subsequent quarters [63][90] - Management highlighted the importance of addressing unmet needs in autoimmune disorders and the potential for significant market expansion [39][40] Other Important Information - The company has expanded its U.S. ophthalmology sales team from 30 to 46 representatives to promote ILUVIEN, YUTIQ, and Cortrophin Gel [20][48] - A prefilled syringe for Cortrophin Gel is under FDA review, expected to launch in the second quarter of 2025 [44][45] - The company has taken steps to enhance supply security for ILUVIEN and YUTIQ through partnerships and capacity expansions [22][100] Q&A Session Summary Question: Business development and M&A capacity - Management indicated a thoughtful approach to leverage ratios, historically keeping it under three, and expressed intent to pursue additional business development while maintaining balance sheet health [76][78] Question: Gout's contribution to Cortrophin sales - Currently, 15% of Cortrophin's volume comes from gout, which is seen as a gateway indication for new prescribers [80] Question: Access issues for Alimera assets - Management acknowledged access issues for ILUVIEN and YUTIQ due to funding shortfalls in patient assistance programs but remains confident in long-term growth prospects [88][89] Question: Seasonality impact on Cortrophin - Typical Q4 to Q1 dynamics are expected, with a drop in sales followed by sequential growth, supported by strong early trends [90] Question: Transitioning supply from EyePoint to Siegfried - Management confirmed that supply transitions are being managed carefully, with inventory buildup and a focus on maintaining supply security [100][101]

Financial Data and Key Metrics Changes - The company reported record fourth quarter and full year 2024 results, with total revenues of $190.6 million, representing a year-over-year increase of 45% on an as-reported basis and 24% on an organic basis [10][38] - Adjusted non-GAAP EBITDA for the fourth quarter was $50 million, compared to $30.2 million in the prior year period, reflecting strong operational performance [43] - The company raised its 2025 revenue guidance to between $756 million and $776 million, representing growth of 23% to 26% over 2024 [8][44] Business Line Data and Key Metrics Changes - Rare disease was the primary driver of growth, with Cortrophin Gel generating close to $200 million in sales in its third year since launch [9] - Revenues from rare disease more than doubled to $87 million in the fourth quarter, with Cortrophin Gel revenues at $59.4 million, up 42% from the prior year [39] - The generics business delivered $78.6 million in revenues, an increase of 9% over the fourth quarter of 2023, driven by operational excellence and new product launches [20][40] Market Data and Key Metrics Changes - The overall ACTH market is expected to have grown about 25% to approximately $660 million in 2024, with Cortrophin Gel's growth contributing significantly [27] - The company estimates that the addressable patient population for ILUVIEN and YUTIQ is approximately six to ten times higher than the current number of patients on therapy [19][64] - The generics segment is expected to see low double-digit growth in 2025, supported by new product launches and a strong base business [22][46] Company Strategy and Development Direction - The company aims to broaden its presence in the rare disease space, as evidenced by the acquisition of Alimera Sciences [9] - The focus will remain on rare disease as the primary growth driver, with continued investment in R&D and commercial initiatives to support this segment [55] - The company is also expanding its ophthalmology sales team and investing in marketing to increase awareness of its products [13][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for Cortrophin Gel and the overall rare disease market, despite near-term challenges related to market access for ILUVIEN and YUTIQ [19][64] - The company anticipates a typical Q4 to Q1 drop in sales for Cortrophin Gel due to prescription reauthorizations, followed by strong sequential growth in subsequent quarters [44][66] - Management highlighted the importance of addressing unmet needs in autoimmune disorders and inflammatory diseases, which could significantly expand the addressable market for Cortrophin Gel [28] Other Important Information - The company has taken steps to enhance supply security for ILUVIEN and YUTIQ, including extending its partnership with its contract manufacturer [15] - A prefilled syringe for Cortrophin Gel is under FDA review, expected to launch in the second quarter of 2025, aimed at improving patient convenience [30][31] - The company has redefined its reporting segments to better reflect its business structure post-acquisition [38] Q&A Session Summary Question: Business development and M&A capacity - Management indicated a thoughtful approach to leverage ratios, historically keeping it under three, and expressed intent to pursue additional business development and M&A without straining the balance sheet [53][54] Question: Gout's contribution to Cortrophin sales - Currently, 15% of Cortrophin's volume comes from gout, which is seen as a gateway indication for new prescribers [56][57] Question: Access issues for ILUVIEN and YUTIQ - Management acknowledged access issues due to funding shortfalls for patient assistance programs but remains confident in the long-term growth prospects for these products [64][65] Question: Seasonality impact on Cortrophin - Typical Q4 to Q1 dynamics are expected, with a drop in sales followed by sequential growth, supported by strong early trends [66] Question: Transitioning supply from EyePoint to Siegfried - Management is confident in the transition and has built up inventory to ensure supply security during the change [70][73]

PART I. FINANCIAL INFORMATION [ITEM 1. Financial Statements](index=5&type=section&id=ITEM%201.%20Financial%20Statements) Alimera Sciences, Inc.'s unaudited condensed consolidated financial statements and notes for Q2 2024 and FY 2023 are presented [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheets (In thousands) | Metric (In thousands) | June 30, 2024 | December 31, 2023 | | :-------------------- | :------------ | :---------------- | | Cash and cash equivalents | $10,828 | $12,058 | | Accounts receivable, net | $37,079 | $34,545 | | Inventory | $3,455 | $1,879 | | Total current assets | $55,408 | $52,423 | | Total assets | $150,377 | $153,524 | | Total current liabilities | $19,838 | $21,913 | | Notes payable, net of discount | $69,731 | $64,489 | | Total liabilities | $111,589 | $107,354 | | Total stockholders' equity | $38,788 | $46,170 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Condensed Consolidated Statements of Operations (In thousands, except share and per share data) | Metric (In thousands, except share and per share data) | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenue | $27,000 | $17,538 | $50,011 | $31,084 | | Gross profit | $23,169 | $15,113 | $42,827 | $26,631 | | Total operating expenses | $23,246 | $16,321 | $45,206 | $31,141 | | Loss from operations | $(77) | $(1,208) | $(2,379) | $(4,510) | | Net loss before income taxes | $(3,354) | $(10,004) | $(9,637) | $(14,972) | | Net loss | $(3,311) | $(10,029) | $(9,562) | $(14,997) | | Net loss applicable to common stockholders | $(3,311) | $(10,698) | $(9,562) | $(15,680) | | Net loss per share — basic and diluted | $(0.06) | $(1.32) | $(0.18) | $(2.07) | [Condensed Consolidated Statements of Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Condensed Consolidated Statements of Comprehensive Loss (In thousands) | Metric (In thousands) | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :-------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net loss | $(3,311) | $(10,029) | $(9,562) | $(14,997) | | Foreign currency translation adjustments | $(51) | — | $(199) | $172 | | Total other comprehensive (loss) income | $(51) | — | $(199) | $172 | | Comprehensive loss | $(3,362) | $(10,029) | $(9,761) | $(14,825) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Condensed Consolidated Statements of Cash Flows (In thousands) | Metric (In thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :-------------------- | :----------------------------- | :----------------------------- | | Net cash provided by (used in) operating activities | $460 | $(8,205) | | Net cash used in investing activities | $(132) | $(75,443) | | Net cash (used in) provided by financing activities | $(1,348) | $97,123 | | Net change in cash and cash equivalents and restricted cash | $(1,229) | $13,503 | | Cash and cash equivalents and restricted cash — end of period | $10,861 | $18,807 | [Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity%20(Deficit)) Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (In thousands, except share data) | Metric (In thousands, except share data) | Balance, December 31, 2023 | Balance, June 30, 2024 | | :--------------------------------------- | :------------------------- | :--------------------- | | Common Shares | 52,354,450 | 52,387,763 | | Common Stock Amount | $524 | $524 | | Additional Paid-In Capital | $462,446 | $464,825 | | Accumulated Deficit | $(418,490) | $(428,052) | | Accumulated Other Comprehensive Loss | $(2,706) | $(2,905) | | Total Stockholders' Equity | $46,170 | $38,788 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed notes on Alimera Sciences, Inc.'s accounting policies, significant transactions, and financial position [1. NATURE OF OPERATIONS](index=11&type=section&id=1.%20NATURE%20OF%20OPERATIONS) Alimera Sciences, Inc. specializes in ophthalmic retinal pharmaceuticals and is undergoing a merger with ANI Pharmaceuticals, Inc. - Alimera Sciences, Inc. specializes in ophthalmic retinal pharmaceuticals, focusing on DME and NIU-PS with **ILUVIEN®** and **YUTIQ®** products[31](index=31&type=chunk) - The Company entered a Merger Agreement with ANI Pharmaceuticals, Inc. on June 21, 2024, where shareholders will receive **$5.50 in cash** and one contingent value right (CVR) per share[36](index=36&type=chunk)[49](index=49&type=chunk) - CVRs entitle holders to potential milestone payments based on **$140.0 million** (2026) and **$160.0 million** (2027) net revenue targets for ILUVIEN and YUTIQ[49](index=49&type=chunk)[50](index=50&type=chunk) [2. BASIS OF PRESENTATION](index=14&type=section&id=2.%20BASIS%20OF%20PRESENTATION) Interim financial statements are prepared under U.S. GAAP and SEC regulations, with management anticipating sufficient liquidity - Interim financial statements are prepared in accordance with **U.S. GAAP** and **SEC regulations**, to be read with the 2023 Annual Report on Form 10-K[52](index=52&type=chunk)[53](index=53&type=chunk) - As of June 30, 2024, cash and cash equivalents totaled **$10.9 million**, with management anticipating sufficient cash flow for the next 12 months[53](index=53&type=chunk) [3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=16&type=section&id=3.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This section outlines the Company's key accounting policies, including asset acquisitions, foreign currency translation, and recent ASU adoptions - Pharmaceutical product licenses are accounted for as **asset acquisitions**, with costs assigned based on relative fair values[55](index=55&type=chunk) - Foreign subsidiary financial statements are translated into **U.S. dollars**, with translation adjustments in accumulated other comprehensive income (loss)[56](index=56&type=chunk) - ASU No. 2022-03 (Fair Value Measurement) and ASU No. 2023-07 (Segment Reporting) were adopted effective January 1, 2024, with **no material financial impact**[56](index=56&type=chunk)[57](index=57&type=chunk) - New accounting standards, including ASU 2023-09 (Income Tax Disclosures), are not yet effective, with ASU 2023-09 effective January 1, 2025[58](index=58&type=chunk)[59](index=59&type=chunk)[60](index=60&type=chunk) [4. REVENUE RECOGNITION](index=18&type=section&id=4.%20REVENUE%20RECOGNITION) Revenue is recognized upon customer control of goods/services, including variable consideration and collaboration/license fees - Revenue is recognized when customers obtain control of goods or services, including estimates for **variable consideration** like rebates and discounts[62](index=62&type=chunk)[64](index=64&type=chunk)[65](index=65&type=chunk) - Collaboration and license revenue from upfront fees and milestone payments are recognized upon **IP delivery** or achieving **high-probability sales targets**[71](index=71&type=chunk)[73](index=73&type=chunk) Provision for Credit Losses (In thousands) | Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :----------------------------- | :----------------------------- | | Beginning balance | $1,222 | $— | | Provision for credit losses | $176 | $1,496 | | Write-off of bad debt | $(1,212) | $(1,311) | | Ending Balance | $186 | $185 | [5. LEASES](index=22&type=section&id=5.%20LEASES) The Company applies FASB ASC 842 for leases, with practical expedients for transition and specific accounting for ROU assets and liabilities - The Company applies **FASB ASC 842 – Leases**, electing practical expedients and not recognizing ROU assets/liabilities for short-term leases[79](index=79&type=chunk) Operating Lease Supplemental Balance Sheet Information (In thousands) | Metric | June 30, 2024 | December 31, 2023 | | :----- | :------------ | :---------------- | | Right-of-use assets, net | $996 | $1,124 | | Total lease assets | $996 | $1,124 | | Total lease liabilities | $2,226 | $2,460 | Finance Lease Supplemental Balance Sheet Information (In thousands) | Metric | June 30, 2024 | December 31, 2023 | | :----- | :------------ | :---------------- | | Property and equipment, net | $589 | $554 | | Total lease assets | $589 | $554 | | Total lease liabilities | $489 | $450 | - Operating lease costs were **$0.1 million** (three months) and **$0.3 million** (six months) ended June 30, 2024[82](index=82&type=chunk) - Cash paid for operating leases was **$0.2 million** for both periods, while finance lease payments were **$0.1 million** and **$0.2 million** respectively[84](index=84&type=chunk)[90](index=90&type=chunk) [6. INVENTORY](index=24&type=section&id=6.%20INVENTORY) Inventories are valued at the lower of cost or net realizable value using the FIFO method, comprising component parts, work-in-progress, and finished goods - Inventories are valued at the **lower of cost or net realizable value** using the FIFO method, including component parts, work-in-progress, and finished goods[92](index=92&type=chunk) Inventory Composition (In thousands) | Inventory Type | June 30, 2024 | December 31, 2023 | | :------------- | :------------ | :---------------- | | Component parts | $653 | $688 | | Work-in-process | $308 | $134 | | Finished goods | $2,494 | $1,057 | | Total Inventory | $3,455 | $1,879 | [7. INTANGIBLE ASSETS](index=26&type=section&id=7.%20INTANGIBLE%20ASSETS) This section details the amortization and carrying amounts of ILUVIEN and YUTIQ intangible assets - The **ILUVIEN** intangible asset has a gross carrying amount of **$25.0 million**, with amortization expense of **$0.5 million** (three months) and **$1.0 million** (six months)[95](index=95&type=chunk) - The **YUTIQ** intangible asset, acquired for **$75.0 million** upfront, has a gross carrying amount of **$96.4 million**, with amortization expense of **$2.4 million** (three months) and **$4.8 million** (six months)[98](index=98&type=chunk) [8. LICENSE AGREEMENTS](index=26&type=section&id=8.%20LICENSE%20AGREEMENTS) This section details the Company's exclusive license agreements for ILUVIEN and YUTIQ, including royalties and milestone payments - The Company holds a worldwide exclusive license from EyePoint for **ILUVIEN** technology, with royalties payable on global net revenues[101](index=101&type=chunk)[102](index=102&type=chunk) - Alimera acquired exclusive commercialization rights to **YUTIQ** for **$75.0 million** upfront, plus **$7.5 million** in guaranteed 2024 quarterly payments and future royalties[104](index=104&type=chunk) - A June 19, 2024, agreement with SWK Funding, LLC modified the royalty payment to **3.125%** on FAc product net revenues, with a change of control buyout option[109](index=109&type=chunk) - An exclusive license agreement with Ocumension (Hong Kong) Limited for **ILUVIEN** in Asia included a **$10.0 million** upfront payment and potential **$89.0 million** in milestone payments[113](index=113&type=chunk)[114](index=114&type=chunk) - Royalty expense was **$0.8 million** (three months) and **$1.7 million** (six months) ended June 30, 2024, an increase from 2023[111](index=111&type=chunk) [9. LOAN AGREEMENTS](index=30&type=section&id=9.%20LOAN%20AGREEMENTS) This section details the Company's loan agreements, including refinancing, interest rates, and exit fee arrangements - The 2019 loan agreement with SLR Investment Corp. was refinanced and amended, increasing the facility to **$72.5 million** as of March 6, 2024[118](index=118&type=chunk)[123](index=123&type=chunk) - The 2019 Loan Agreement's interest rate was approximately **10.48%** as of June 30, 2024, with interest-only payments until April 30, 2025[124](index=124&type=chunk) - SLR exit fees, totaling up to **$3.8 million**, were triggered by revenue milestones, recognizing **$1.1 million** (Q1) and **$0.3 million** (Q2) in interest expense[126](index=126&type=chunk)[127](index=127&type=chunk)[128](index=128&type=chunk)[129](index=129&type=chunk)[130](index=130&type=chunk) [10. EARNINGS (LOSS) PER SHARE](index=34&type=section&id=10.%20EARNINGS%20(LOSS)%20PER%20SHARE) Basic and diluted EPS calculations are presented, noting that net losses render common stock equivalents anti-dilutive - Basic and diluted EPS are calculated using the **two-class method**, though preferred stockholders are not obligated to share in losses[135](index=135&type=chunk) - Due to net losses, basic and diluted net loss per share were identical, as common stock equivalents were **anti-dilutive**[136](index=136&type=chunk) Common Stock Equivalents Excluded from Diluted Net Loss Per Share Calculation | Metric | June 30, 2024 | June 30, 2023 | | :----- | :------------ | :------------ | | Common stock warrants | 1,600,000 | 1,600,000 | | Stock options | 3,275,893 | 1,217,045 | | Restricted stock units ("RSUs") | 869,638 | — | | Performance stock units ("PSUs") | 900,000 | — | | Total | 6,645,531 | 48,089,919 | [11. STOCKHOLDERS' EQUITY](index=34&type=section&id=11.%20STOCKHOLDERS'%20EQUITY) This section details changes in stockholders' equity, including preferred stock elimination and common stock issuance - The Company repurchased and eliminated all remaining **600,000 shares** of Series A Convertible Preferred Stock in 2023[139](index=139&type=chunk) - In 2023, Series B Convertible Preferred Stock was issued for **$79.0 million**, converting into **43,617,114 common shares** and Pre-Funded Warrants[140](index=140&type=chunk)[141](index=141&type=chunk)[142](index=142&type=chunk) - As of June 30, 2024, **52,387,763 common shares** were outstanding, with no preferred stock outstanding[142](index=142&type=chunk) [12. STOCK-BASED COMPENSATION](index=36&type=section&id=12.%20STOCK-BASED%20COMPENSATION) This section details stock-based compensation expenses, equity incentive plans, and stock option/RSU/PSU activity - The **2023 Equity Incentive Plan** replaced the 2019 Plan, with a share reserve increasing annually by **6%** of outstanding common stock[144](index=144&type=chunk)[145](index=145&type=chunk) - Stock option compensation expense was approximately **$0.5 million** (three months) and **$1.0 million** (six months), with **$4.5 million** unrecognized[147](index=147&type=chunk) Stock Option Activity (Three Months Ended June 30) | Metric | 2024 Options | Weighted Average Exercise Price ($) | 2023 Options | Weighted Average Exercise Price ($) | | :----- | :----------- | :---------------------------------- | :----------- | :---------------------------------- | | Options outstanding at beginning of period | 3,239,384 | 7.38 | 1,216,953 | 18.03 | | Grants | 64,000 | 3.00 | 17,321 | 2.55 | | Forfeitures and expirations | (27,491) | 12.80 | (17,229) | 45.18 | | Options outstanding at period end | 3,275,893 | 7.25 | 1,217,045 | 17.43 | - Restricted stock and RSU compensation expense was **$0.3 million** (three months) and **$0.6 million** (six months), with **$3.0 million** unrecognized[160](index=160&type=chunk)[161](index=161&type=chunk) - PSU compensation costs were **$0.9 million** for both periods, with **299,999 PSUs** vesting in July 2024[165](index=165&type=chunk) [13. INCOME TAXES](index=42&type=section&id=13.%20INCOME%20TAXES) This section discusses deferred tax assets, valuation allowances, and net operating loss carry-forwards - Deferred tax assets and liabilities are recognized, with a **full valuation allowance** against U.S. deferred tax assets due to operating losses[168](index=168&type=chunk) - A tax benefit of less than **$0.1 million** was recorded for both periods, with the effective tax rate impacted by valuation allowances[170](index=170&type=chunk) - As of December 31, 2023, federal NOL carry-forwards were **$146.8 million** and state NOLs were **$106.8 million**, subject to Section 382 limitations[170](index=170&type=chunk)[171](index=171&type=chunk) [14. SEGMENT INFORMATION](index=44&type=section&id=14.%20SEGMENT%20INFORMATION) Operations are managed as three reportable segments: U.S., International, and Operating Cost, evaluated by adjusted segment income or loss - Operations are managed as three reportable segments: **U.S., International, and Operating Cost**, evaluated by adjusted segment income or loss[175](index=175&type=chunk) - For Q2 2024, U.S. segment net revenue was **$17.6 million** (**65%** of consolidated), and International segment net revenue was **$9.4 million**[179](index=179&type=chunk) - For H1 2024, U.S. segment net revenue was **$32.1 million** (**64%** of consolidated), and International segment net revenue was **$17.9 million**[184](index=184&type=chunk) - Two large U.S. distributors accounted for **65%** (three months) and **64%** (six months) of consolidated product revenues[178](index=178&type=chunk) [15. FAIR VALUE](index=46&type=section&id=15.%20FAIR%20VALUE) This section outlines the Company's fair value measurements, including the hierarchy and valuation of derivative instruments - The Company applies **FASB ASC 820, Fair Value Measurements**, establishing a hierarchy based on input observability[186](index=186&type=chunk)[187](index=187&type=chunk) - The Ocumension warrant asset is a **Level 2 derivative instrument**, valued using the Black-Scholes model, with changes in the statement of operations[188](index=188&type=chunk)[191](index=191&type=chunk) Assets Measured at Fair Value (In thousands) | Metric | Level 1 | Level 2 | Level 3 | Total | | :----- | :------ | :------ | :------ | :---- | | Warrant asset (June 30, 2024) | $— | $7 | $— | $7 | | Warrant asset (December 31, 2023) | $— | $52 | $— | $52 | [16. SUBSEQUENT EVENTS](index=48&type=section&id=16.%20SUBSEQUENT%20EVENTS) This section reports significant events occurring after the reporting period, including new manufacturing agreements and equity vesting - On July 17, 2024, a new Manufacturing Services Agreement was entered with Siegfried Irvine for **ILUVIEN** manufacturing and supply[192](index=192&type=chunk) - In July 2024, **299,999 PSUs** vested, and in August 2024, Pre-Funded Warrants were exercised for **1,996,402 common shares**[194](index=194&type=chunk) [ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=49&type=section&id=ITEM%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Alimera Sciences, Inc.'s financial condition, operations, merger activities, products, market, and liquidity for Q2 2024 and FY 2023 [Overview](index=49&type=section&id=Overview) Alimera Sciences, Inc. is a global pharmaceutical company focused on improving retinal health through long-term treatment of chronic retinal diseases - Alimera Sciences, Inc. is a global ophthalmic retinal pharmaceutical company, improving retinal health with **ILUVIEN®** and **YUTIQ®**[196](index=196&type=chunk) [Agreement and Plan of Merger with ANI Pharmaceuticals, Inc. and ANIP Merger Sub INC.](index=49&type=section&id=Agreement%20and%20Plan%20of%20Merger%20with%20ANI%20Pharmaceuticals,%20Inc.%20and%20ANIP%20Merger%20Sub%20INC.) This section details the merger agreement with ANI Pharmaceuticals, Inc., including terms, conditions, and associated costs - On June 21, 2024, Alimera entered a Merger Agreement with ANI Pharmaceuticals, Inc., converting each common share into **$5.50 cash** and one CVR[197](index=197&type=chunk) - The merger is subject to customary closing conditions, including **regulatory and stockholder approvals**, with Alimera restricted from soliciting alternative proposals[198](index=198&type=chunk)[200](index=200&type=chunk) - CVRs offer potential milestone payments based on **$140.0 million** (2026) and **$160.0 million** (2027) net revenue targets for ILUVIEN and YUTIQ[210](index=210&type=chunk)[211](index=211&type=chunk)[213](index=213&type=chunk) - Merger Agreement costs totaled **$2.2 million** for both periods ended June 30, 2024, recorded in general and administrative expenses[215](index=215&type=chunk) [ILUVIEN and YUTIQ](index=53&type=section&id=ILUVIEN%20and%20YUTIQ) This section describes ILUVIEN and YUTIQ, their commercialization, and their CONTINUOUS MICRODOSING™ technology - **ILUVIEN** (0.19 mg) is commercialized for DME and NIU-PS globally, while **YUTIQ** (0.18 mg) is for chronic NIU-PS in the U.S[216](index=216&type=chunk) - Both products use **CONTINUOUS MICRODOSING™** to deliver consistent FAc levels for up to three years, mitigating side effects and reducing recurrence[217](index=217&type=chunk)[218](index=218&type=chunk)[225](index=225&type=chunk) [Disease Overview and Market Opportunity](index=55&type=section&id=Disease%20Overview%20and%20Market%20Opportunity) This section outlines the market opportunity for DME and uveitis, and ongoing clinical studies for ILUVIEN and YUTIQ - DME affects **750,000 people** in the U.S., and chronic NIU-PS affects **60,000-100,000 people** annually, both leading causes of blindness[227](index=227&type=chunk)[228](index=228&type=chunk)[231](index=231&type=chunk) - The **NEW DAY Study** (300 DME patients) evaluates ILUVIEN, with data expected in 2025; the **SYNCHRONICITY Study** (110 patient eyes) evaluates YUTIQ[232](index=232&type=chunk)[233](index=233&type=chunk)[235](index=235&type=chunk) - ILUVIEN is also being studied in a **DRCR Retina Network trial** for preventing visual acuity loss from radiation retinopathy[237](index=237&type=chunk) [Where We Market ILUVIEN to Treat Diabetic Macular Edema ("DME")](index=58&type=section&id=Where%20We%20Market%20ILUVIEN%20to%20Treat%20Diabetic%20Macular%20Edema%20(%22DME%22)) This section lists territories where ILUVIEN is authorized, reimbursed, and available for treating Diabetic Macular Edema (DME) ILUVIEN Marketing Authorization, Reimbursement, and Availability for DME | Category | Territories | | :------- | :---------- | | Indication for Treatment of DME | U.S., Australia, Bahrain, United Arab Emirates, U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Norway, Poland, the Netherlands, Luxembourg | | Territories Where ILUVIEN Has Received Reimbursement Approval to Treat DME | U.S., Kuwait, Lebanon, United Arab Emirates, U.K., Germany, France, Italy, Spain, Portugal, Ireland, Luxembourg, the Netherlands | | Territories Where ILUVIEN is Currently Available to Treat DME | U.S., Bahrain, Kuwait, Lebanon, United Arab Emirates, U.K., Belgium, Czech Republic, Germany, France, Italy, Spain, Portugal, Ireland, Austria, Luxembourg, Denmark, Norway, Finland, Sweden, the Netherlands | [Where We Market ILUVIEN and YUTIQ to Treat Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye ("NIU-PS")](index=58&type=section&id=Where%20We%20Market%20ILUVIEN%20and%20YUTIQ%20to%20Treat%20Chronic%20Non-Infectious%20Uveitis%20Affecting%20the%20Posterior%20Segment%20of%20the%20Eye%20(%22NIU-PS%22)) This section lists territories where ILUVIEN and YUTIQ are authorized, reimbursed, and available for treating chronic NIU-PS ILUVIEN and YUTIQ Marketing Authorization, Reimbursement, and Availability for NIU-PS | Category | Territories | | :------- | :---------- | | Indication for the Treatment of NIU-PS | U.S. (YUTIQ), U.K., Germany, France, Spain, Portugal, Ireland, Italy, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands, Luxembourg, United Arab Emirates (ILUVIEN) | | Territories Where ILUVIEN Has Received Marketing Authorization to Treat NIU-PS | U.K., Germany, France, Spain, Portugal, Ireland, Italy, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands, Luxembourg, United Arab Emirates | | Territories Where ILUVIEN Has Received Reimbursement Approval to Treat NIU-PS | U.K., Germany, Ireland, Italy, France, Portugal, Spain, Czech Republic, Luxembourg, the Netherlands | | Territories Where ILUVIEN is Currently Marketed to Treat NIU-PS | U.K., Germany, France, Spain, Portugal, Ireland, Italy, Austria, Belgium, Denmark, Norway, Finland, Sweden, Czech Republic, the Netherlands, Luxembourg, United Arab Emirates | [Where We Sell ILUVIEN Direct](index=58&type=section&id=Where%20We%20Sell%20ILUVIEN%20Direct) This section identifies the countries where Alimera Sciences, Inc. directly markets and sells ILUVIEN - Alimera commercially markets **ILUVIEN** directly in the U.S., Germany, the U.K., Portugal, and Ireland[243](index=243&type=chunk) [Where We Sell ILUVIEN Through Distributors](index=58&type=section&id=Where%20We%20Sell%20ILUVIEN%20Through%20Distributors) This section lists the countries where Alimera Sciences, Inc. sells ILUVIEN through third-party distributors - The Company sells **ILUVIEN** through distributors across Europe, Australia, New Zealand, China, Western Pacific, and the Middle East[244](index=244&type=chunk) [Sources of Revenues](index=59&type=section&id=Sources%20of%20Revenues) Revenue is primarily generated from ILUVIEN and YUTIQ sales, supplemented by licensing fees and royalties - Revenue is primarily from **ILUVIEN** and **YUTIQ** sales, with additional sources including upfront fees, milestone payments, and royalties[264](index=264&type=chunk) - Sales efforts focus on **formulary access**, physician education on product efficacy and safety, and patient/caregiver education[245](index=245&type=chunk)[246](index=246&type=chunk) - For Q2 2024, two large U.S. pharmaceutical distributors accounted for **65%** of consolidated product revenues[247](index=247&type=chunk) [Transactions with Ocumension Therapeutics ("Ocumension")](index=59&type=section&id=Transactions%20with%20Ocumension%20Therapeutics%20(%22Ocumension%22)) This section details the exclusive license agreement with Ocumension for ILUVIEN in Asia, including upfront payments and warrants - An exclusive license agreement with Ocumension for **ILUVIEN** in Asia included a **$10.0 million** upfront payment and potential **$89.0 million** in milestone payments[248](index=248&type=chunk)[250](index=250&type=chunk) - The Company received **1,000,000 non-transferable warrants** from Ocumension, revalued at each reporting date[252](index=252&type=chunk) [Agreements with EyePoint Parent and EyePoint](index=60&type=section&id=Agreements%20with%20EyePoint%20Parent%20and%20EyePoint) This section outlines licensing, collaboration, and supply agreements with EyePoint for ILUVIEN and YUTIQ - Alimera holds a worldwide license from EyePoint for steroid use in its proprietary insert technology for ocular diseases[254](index=254&type=chunk) - The New Collaboration Agreement converted profit share to a royalty of **6%** (up to **$75.0 million**) and **8%** (above), with a **$15.0 million** Future Offset[255](index=255&type=chunk) - Alimera acquired exclusive commercialization rights to **YUTIQ** for **$75.0 million** upfront, plus **$7.5 million** in guaranteed 2024 quarterly payments and future royalties[256](index=256&type=chunk) - A commercial supply agreement with EyePoint Parent ensures exclusive **YUTIQ** supply for U.S. commercialization until May 2025, with automatic renewals[257](index=257&type=chunk) [SWK Agreements](index=61&type=section&id=SWK%20Agreements) This section details agreements with SWK Funding, LLC, including royalty sales and modifications to royalty payments - EyePoint sold its royalty interest under the New Collaboration Agreement to **SWK Funding, LLC** in December 2020[259](index=259&type=chunk) - A June 19, 2024, agreement with SWK modified the royalty payment to **3.125%** on FAc product net revenues, with a change of control buyout option[260](index=260&type=chunk) [Consolidated Results of Operations](index=62&type=section&id=Consolidated%20Results%20of%20Operations) This section provides a consolidated overview of the Company's financial performance, including revenue, expenses, and net loss per share [Revenue](index=62&type=section&id=Revenue) Net revenue increased significantly, driven by YUTIQ acquisition and higher ILUVIEN unit sales Net Revenue (In thousands) | Period | 2024 | 2023 | Change ($) | Change (%) | | :----- | :--- | :--- | :--------- | :--------- | | Three Months Ended June 30 | $27,000 | $17,538 | $9,462 | 54% | | Six Months Ended June 30 | $50,011 | $31,084 | $18,927 | 61% | - Net revenue increase was primarily driven by **YUTIQ** in the U.S. segment and increased **ILUVIEN** unit sales internationally[264](index=264&type=chunk)[265](index=265&type=chunk) [Cost of Goods Sold, Excluding Depreciation and Amortization, and Gross Profit](index=62&type=section&id=Cost%20of%20Goods%20Sold,%20Excluding%20Depreciation%20and%20Amortization,%20and%20Gross%20Profit) Cost of goods sold increased due to higher product sales, while gross profit and margin remained stable Cost of Goods Sold (COGS) and Gross Profit (In thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | COGS (excluding D&A) | $(3,831) | $(2,425) | $(7,184) | $(4,453) | | Gross Profit | $23,169 | $15,113 | $42,827 | $26,631 | | Gross Margin | 86% | 86% | 86% | 86% | - COGS increase was primarily due to increased product sales, driven by the **YUTIQ acquisition** and higher **ILUVIEN** unit sales[266](index=266&type=chunk)[268](index=268&type=chunk) [Research, Development and Medical Affairs Expenses](index=63&type=section&id=Research,%20Development%20and%20Medical%20Affairs%20Expenses) Research, development, and medical affairs expenses increased due to higher consultant, clinical study, and personnel costs Research, Development and Medical Affairs Expenses (In thousands) | Period | 2024 | 2023 | Change ($) | Change (%) | | :----- | :--- | :--- | :--------- | :--------- | | Three Months Ended June 30 | $4,263 | $3,648 | $615 | 17% | | Six Months Ended June 30 | $8,624 | $7,812 | $812 | 10% | - The increase was primarily due to higher **consultant, clinical study, personnel, and ILUVIEN registration costs**[271](index=271&type=chunk)[272](index=272&type=chunk) [General and Administrative Expenses](index=64&type=section&id=General%20and%20Administrative%20Expenses) General and administrative expenses increased significantly, mainly due to professional fees related to the ANI Merger Agreement General and Administrative Expenses (In thousands) | Period | 2024 | 2023 | Change ($) | Change (%) | | :----- | :--- | :--- | :--------- | :--------- | | Three Months Ended June 30 | $7,379 | $4,373 | $3,006 | 68% | | Six Months Ended June 30 | $12,811 | $8,544 | $4,267 | 51% | - The increase was mainly driven by **$2.0 million** in professional fees for the ANI Merger Agreement, higher personnel costs, and stock-based compensation[274](index=274&type=chunk) [Sales and Marketing Expenses](index=64&type=section&id=Sales%20and%20Marketing%20Expenses) Sales and marketing expenses increased due to higher personnel costs and expanded marketing efforts for YUTIQ Sales and Marketing Expenses (In thousands) | Period | 2024 | 2023 | Change ($) | Change (%) | | :----- | :--- | :--- | :--------- | :--------- | | Three Months Ended June 30 | $8,511 | $6,434 | $2,077 | 33% | | Six Months Ended June 30 | $17,593 | $12,238 | $5,355 | 44% | - The increase was primarily due to higher **personnel costs** and increased marketing costs for **YUTIQ**, conventions, and customer engagement[276](index=276&type=chunk) [Operating Expenses](index=64&type=section&id=Operating%20Expenses) Total operating expenses increased significantly, driven by merger-related costs, sales and marketing expansion, and amortization Total Operating Expenses (In thousands) | Period | 2024 | 2023 | Change ($) | Change (%) | | :----- | :--- | :--- | :--------- | :--------- | | Three Months Ended June 30 | $23,246 | $16,321 | $6,925 | 42% | | Six Months Ended June 30 | $45,206 | $31,141 | $14,065 | 45% | - Total operating expenses increased due to **$2.2 million** in merger-related G&A, **$1.8 million** in sales/marketing expansion, **$1.2 million** in YUTIQ amortization, and **$1.2 million** in stock compensation[263](index=263&type=chunk)[277](index=277&type=chunk) [Interest Expense and Other, Net](index=65&type=section&id=Interest%20Expense%20and%20Other,%20Net) Interest expense increased significantly due to triggered exit fees and higher interest on additional borrowings Interest Expense and Other, Net (In thousands) | Period | 2024 | 2023 | Change ($) | Change (%) | | :----- | :--- | :--- | :--------- | :--------- | | Three Months Ended June 30 | $3,153 | $1,694 | $1,459 | 86% | | Six Months Ended June 30 | $6,892 | $3,361 | $3,531 | 105% | - The increase was primarily due to **$1.4 million** in triggered exit fees and increased interest on additional borrowings[263](index=263&type=chunk)[279](index=279&type=chunk) [Basic and Diluted Net Loss Applicable to Common Stockholders per Share of Common Stock](index=65&type=section&id=Basic%20and%20Diluted%20Net%20Loss%20Applicable%20to%20Common%20Stockholders%20per%20Share%20of%20Common%20Stock) Basic and diluted net loss per share were identical due to net losses, rendering potentially dilutive securities anti-dilutive Net Loss Per Share | Period | 2024 | 2023 | | :----- | :--- | :--- | | Three Months Ended June 30 | $(0.06) | $(1.32) | | Six Months Ended June 30 | $(0.18) | $(2.07) | - Basic and diluted net loss per share were identical due to net losses, making potentially dilutive securities **anti-dilutive**[263](index=263&type=chunk)[280](index=280&type=chunk)[281](index=281&type=chunk) [Results of Operations – Segment Review](index=65&type=section&id=Results%20of%20Operations%20%E2%80%93%20Segment%20Review) This section reviews the financial performance of the U.S., International, and Operating Cost segments, highlighting key revenue and expense drivers - Segments (U.S., International, Operating Cost) are evaluated based on **segment income or loss**, adjusted for non-cash items[283](index=283&type=chunk) [U.S. Segment Results](index=65&type=section&id=U.S.%20Segment%20Results) U.S. segment net revenue increased significantly, driven by the YUTIQ acquisition, while G&A decreased and S&M increased U.S. Segment Net Revenue and Gross Profit (In thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenue | $17,558 | $11,876 | $32,110 | $19,456 | | Gross profit | $15,633 | $10,586 | $28,761 | $17,261 | - U.S. net revenue increased by **48%** (three months) and **65%** (six months), primarily driven by the **YUTIQ acquisition**[285](index=285&type=chunk)[288](index=288&type=chunk)[291](index=291&type=chunk) - U.S. G&A expenses decreased by **73%** (three months) and **59%** (six months), mainly due to reduced bad debt and insurance costs[289](index=289&type=chunk)[292](index=292&type=chunk) - U.S. S&M expenses increased by **23%** (three months) and **42%** (six months), driven by higher personnel and **YUTIQ** marketing costs[290](index=290&type=chunk)[293](index=293&type=chunk) [International Segment Results](index=67&type=section&id=International%20Segment%20Results) International net revenue increased significantly due to distributor stocking and end-user demand, with higher sales and marketing expenses International Segment Net Revenue and Gross Profit (In thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenue | $9,442 | $5,662 | $17,901 | $11,628 | | Gross profit | $7,536 | $4,527 | $14,066 | $9,370 | - International net revenue increased by **65%** (three months) and **54%** (six months), driven by increased distributor stocking and end-user demand[294](index=294&type=chunk)[296](index=296&type=chunk)[298](index=298&type=chunk) - International S&M expenses increased by **29%** (three months) and **21%** (six months), primarily due to higher marketing and personnel costs[297](index=297&type=chunk)[299](index=299&type=chunk) [Operating Cost Segment Results](index=69&type=section&id=Operating%20Cost%20Segment%20Results) Operating Cost segment expenses increased, primarily driven by professional fees related to the ANI Merger Agreement Operating Cost Segment Expenses (In thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research, development and medical affairs expenses | $2,137 | $1,033 | $4,462 | $3,266 | | General and administrative expenses | $5,263 | $2,619 | $8,920 | $4,814 | | Sales and marketing expenses | $474 | $225 | $908 | $291 | | Total operating expenses | $7,874 | $3,877 | $14,290 | $8,371 | - Operating Cost G&A expenses increased by **104%** (three months) and **85%** (six months), largely due to **$2.0 million** in ANI Merger Agreement professional fees[300](index=300&type=chunk)[301](index=301&type=chunk)[303](index=303&type=chunk)[304](index=304&type=chunk) [Other](index=71&type=section&id=Other) Other operating expenses increased significantly, mainly due to higher depreciation, amortization, and stock compensation Other Operating Expenses (In thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Total operating expenses | $4,552 | $2,083 | $8,481 | $2,989 | | Depreciation and amortization | $3,093 | $1,866 | $6,178 | $2,547 | - Operating expenses in 'Other' increased by **119%** (three months) and **183%** (six months), primarily due to higher depreciation, amortization from **YUTIQ**, and increased stock compensation[306](index=306&type=chunk)[307](index=307&type=chunk)[308](index=308&type=chunk) [Liquidity and Capital Resources](index=71&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the Company's cash position, funding outlook, debt, and equity transactions [Overview](index=71&type=section&id=Overview) The Company has incurred recurring losses and negative cash flow, but anticipates sufficient liquidity for the next 12 months, assuming merger consummation - The Company incurred recurring losses and negative cash flow, with a stockholders' equity deficit of **$428.1 million** as of June 30, 2024[309](index=309&type=chunk) - As of June 30, 2024, cash and equivalents totaled **$10.9 million**, with sufficient funding anticipated for 12 months, assuming merger consummation[310](index=310&type=chunk)[311](index=311&type=chunk) - Non-consummation of the merger may necessitate alternative financing, potentially leading to **substantial dilution** or requiring lender permission[311](index=311&type=chunk) [Sources and Uses of Cash for the six months ended June 30, 2024 compared to the six months ended June 30, 2023](index=73&type=section&id=Sources%20and%20Uses%20of%20Cash%20for%20the%20six%20months%20ended%20June%2030,%202024%20compared%20to%20the%20six%20months%20ended%20June%2030,%202023) Operating cash flow improved significantly, while investing activities decreased and financing activities shifted to net cash used - Net cash provided by operating activities was **$0.5 million**, a significant improvement from **$8.2 million used** in the prior year[313](index=313&type=chunk)[314](index=314&type=chunk) - Net cash used in investing activities was **$0.1 million**, significantly lower than **$75.4 million** in 2023, which included intangible asset acquisition[315](index=315&type=chunk) - Net cash used in financing activities was **$1.3 million**, primarily due to licensor obligations and exit fees, partially offset by **$5.0 million** from loan amendment[315](index=315&type=chunk) [Indebtedness](index=73&type=section&id=Indebtedness) This section details the Company's loan agreements, including facility increases, interest-only periods, and compliance with covenants - The 2019 Loan Agreement with SLR Investment Corp. was amended, increasing the facility to **$72.5 million**, with interest-only payments until April 30, 2025[317](index=317&type=chunk)[322](index=322&type=chunk) - The Company maintained compliance with its **revenue covenant**, with non-compliance potentially accelerating loan maturity[324](index=324&type=chunk) - Increased **SOFR rates** would raise interest costs, potentially impacting operations and debt obligations[323](index=323&type=chunk) [Series A Convertible Preferred Stock and Elimination](index=76&type=section&id=Series%20A%20Convertible%20Preferred%20Stock%20and%20Elimination) The Company repurchased and eliminated all remaining Series A Convertible Preferred Stock in 2023 - In 2023, the Company repurchased and eliminated the remaining **600,000 shares** of Series A Convertible Preferred Stock[325](index=325&type=chunk) [Series B Preferred Stock Financings and Elimination](index=77&type=section&id=Series%20B%20Preferred%20Stock%20Financings%20and%20Elimination) Series B Convertible Preferred Stock was issued and subsequently converted into common shares and Pre-Funded Warrants - In 2023, Series B Convertible Preferred Stock was issued for **$79.0 million**, converting into **43,617,114 common shares** and Pre-Funded Warrants[327](index=327&type=chunk) - In August 2024, Pre-Funded Warrants were exercised for **1,996,402 common shares**, with no remaining outstanding warrants[328](index=328&type=chunk) [Common and Preferred Stock](index=77&type=section&id=Common%20and%20Preferred%20Stock) The Company's authorized capital stock includes common and preferred shares, with only common shares outstanding as of June 30, 2024 - Authorized capital includes **150,000,000 common shares** and **10,000,000 preferred shares**; **52,387,763 common shares** were outstanding as of June 30, 2024[329](index=329&type=chunk) [Contractual Obligations and Commitments](index=77&type=section&id=Contractual%20Obligations%20and%20Commitments) This section details contractual obligations, including clinical study expenses and manufacturing agreements - The **NEW DAY Study** incurred **$0.6 million** (three months) and **$1.6 million** (six months) in expenses, with **$1.5 million** expected for H2 2024[330](index=330&type=chunk) - A new Manufacturing Services Agreement with Siegfried Irvine for **ILUVIEN** manufacturing was entered on July 17, 2024, with a five-year term[332](index=332&type=chunk) - The Cadence Agreement for **ILUVIEN** applicator component manufacturing expires October 30, 2025, with less than **$1.0 million** expected for H2 2024[333](index=333&type=chunk)[334](index=334&type=chunk) [Off-Balance Sheet Arrangements](index=79&type=section&id=Off-Balance%20Sheet%20Arrangements) The Company has no relationships with unconsolidated entities or financial partnerships resulting in off-balance sheet arrangements - The Company has **no off-balance sheet arrangements** with unconsolidated entities or financial partnerships[336](index=336&type=chunk) [Impact of Recent Accounting Pronouncements](index=79&type=section&id=Impact%20of%20Recent%20Accounting%20Pronouncements) Refer to Note 3 in the Interim Financial Statements for details on recent accounting pronouncements and their anticipated effects - Refer to **Note 3** in the Interim Financial Statements for details on recent accounting pronouncements and their anticipated effects[337](index=337&type=chunk) [Foreign Exchange](index=79&type=section&id=Foreign%20Exchange) Fluctuations in foreign currency exchange rates negatively impacted net product revenue for the six months ended June 30, 2024 - Foreign currency exchange rate fluctuations decreased net product revenue by approximately **$0.1 million** for the six months ended June 30, 2024[338](index=338&type=chunk) [Non-GAAP Financial Measure](index=79&type=section&id=Non-GAAP%20Financial%20Measure) The Company provides non-GAAP Adjusted EBITDA to offer additional insight into its underlying performance - The Company provides **non-GAAP Adjusted EBITDA** for additional insight into underlying performance, used consistently by management[339](index=339&type=chunk) Reconciliation of U.S. GAAP Net Loss to Non-GAAP Adjusted EBITDA (In thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | U.S. GAAP net loss | $(3,311) | $(10,029) | $(9,562) | $(14,997) | | Non-GAAP adjusted EBITDA | $6,714 | $875 | $8,518 | $(1,521) | [ITEM 3. Quantitative and Qualitative Disclosures about Market Risk](index=79&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, Alimera Sciences, Inc. is exempt from providing market risk disclosures in its Form 10-Q - The Company is exempt from market risk disclosures as it qualifies as a **"smaller reporting company"**[343](index=343&type=chunk) [ITEM 4. Controls and Procedures](index=81&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Management concluded Alimera Sciences, Inc.'s disclosure controls were effective as of June 30, 2024, with no material changes in internal control - Disclosure controls and procedures were evaluated and deemed **effective** as of June 30, 2024, by management[344](index=344&type=chunk) - No **material changes** in internal control over financial reporting occurred during the three months ended June 30, 2024[345](index=345&type=chunk) - Control systems provide **reasonable assurance**, acknowledging inherent limitations where misstatements may not be detected[346](index=346&type=chunk) PART II. OTHER INFORMATION [ITEM 1. Legal Proceedings](index=81&type=section&id=ITEM%201.%20Legal%20Proceedings) Alimera Sciences, Inc. is not a party to any threatened or pending material litigation and has no contingency reserves - The Company is **not involved** in any threatened or pending material legal proceedings and has no contingency reserves[347](index=347&type=chunk) [ITEM 1A. Risk Factors](index=81&type=section&id=ITEM%201A.%20Risk%20Factors) This section updates risk factors from the 2023 Form 10-K, focusing on economic uncertainties, the pending ANI merger, and manufacturing/regulatory challenges [Economic Uncertainties and Downturns](index=81&type=section&id=Economic%20Uncertainties%20and%20Downturns) Prolonged economic uncertainties, geopolitical tensions, and supply chain disruptions may adversely affect the Company's business - Prolonged economic uncertainties, including **inflationary pressures**, geopolitical tensions, and supply chain disruptions, may adversely affect the business[349](index=349&type=chunk) - Negative economic trends could impact **reimbursement** from government and private insurers, potentially reducing product sales and revenue[350](index=350&type=chunk) [Risks Related to the Pending Merger with ANI Pharmaceuticals](index=82&type=section&id=Risks%20Related%20to%20the%20Pending%20Merger%20with%20ANI%20Pharmaceuticals) Failure to complete the ANI merger could lead to stock price decline, termination fees, business disruption, and differing interests for executives - Failure to complete the merger could lead to stock price decline, a **$10.4 million termination fee**, negative publicity, and diverted management resources[353](index=353&type=chunk)[355](index=355&type=chunk) - Merger pendency could disrupt operations, affect **employee retention**, and strain relationships with collaborators, suppliers, and customers[354](index=354&type=chunk) - Executive officers and directors may have interests in the merger that **differ from stockholders**, including accelerated equity vesting and severance[359](index=359&type=chunk) - If the merger is consummated, stockholders receive cash and CVRs, but **lose equity interests** in the surviving corporation, limiting future upside[360](index=360&type=chunk) [Manufacturing and Regulatory Compliance Risks](index=84&type=section&id=Manufacturing%20and%20Regulatory%20Compliance%20Risks) Non-compliance with cGMP, supplier issues, and changes in manufacturing processes pose significant risks to commercialization and regulatory approvals - Failure to comply with **FDA cGMP** and similar foreign regulations could harm commercialization and approvals, leading to sanctions or production interruptions[360](index=360&type=chunk) - EyePoint Parent, a **YUTIQ** supplier, received an **FDA warning letter** in July 2024 for cGMP violations, potentially affecting YUTIQ supply[360](index=360&type=chunk)[361](index=361&type=chunk) - Changes in manufacturing processes or facilities require **prior FDA review/approval**, potentially delaying product launch or requiring additional clinical testing[362](index=362&type=chunk) [ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=86&type=section&id=ITEM%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Alimera Sciences, Inc. reports no unregistered sales of equity securities or use of proceeds for the period - None reported[365](index=365&type=chunk) [ITEM 3. Defaults Upon Senior Securities](index=86&type=section&id=ITEM%203.%20Defaults%20Upon%20Senior%20Securities) Alimera Sciences, Inc. reports no defaults upon senior securities for the period - None reported[365](index=365&type=chunk) [ITEM 4. Mine Safety Disclosures](index=86&type=section&id=ITEM%204.%20Mine%20Safety%20Disclosures) Mine Safety Disclosures are not applicable to Alimera Sciences, Inc.'s operations - Not applicable[365](index=365&type=chunk) [ITEM 5. Other Information](index=86&type=section&id=ITEM%205.%20Other%20Information) Alimera Sciences, Inc. reports no other information for the period - Not applicable[365](index=365&type=chunk) [ITEM 6. Exhibits](index=87&type=section&id=ITEM%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the Merger Agreement, organizational documents, and certifications - Key exhibits include the **Merger Agreement**, **organizational documents**, **equity incentive plans**, **loan agreements**, **manufacturing services agreements**, and **certifications**[367](index=367&type=chunk) [Signatures](index=88&type=section&id=Signatures) The report was signed by Richard S. Eiswirth, Jr., President and CEO of Alimera Sciences, Inc., on August 7, 2024 - The report was signed by **Richard S. Eiswirth, Jr.**, President and Chief Executive Officer of Alimera Sciences, Inc., on **August 7, 2024**[368](index=368&type=chunk)

Executive Summary [Key Second Quarter Financial Highlights](index=1&type=section&id=Key%20Second%20Quarter%20Financial%20Highlights) Alimera Sciences reported strong financial results for Q2 2024, with significant revenue growth and improved profitability, driven by the integration of YUTIQ and increased international sales | Metric | Q2 2024 (Millions) | Q2 2023 (Millions) | Change (YoY) | | :----------------------- | :----------------- | :----------------- | :----------- | | Net Revenue | $27.0 | $17.5 | +54% | | Net Loss | $(3.3) | $(10.7) | Improved | | Adjusted EBITDA | $6.7 | $0.9 | +644% | | U.S. Net Revenue | $17.6 | $11.9 | +48% | | International Net Revenue| $9.4 | $5.7 | +65% | | Global End User Demand | 3,821 units | N/A | +6% | [Second Quarter Corporate Highlights](index=1&type=section&id=Second%20Quarter%20Corporate%20Highlights) During Q2 2024, Alimera Sciences entered into a definitive merger agreement with ANI Pharmaceuticals and modified its royalty payment terms with SWK Funding LLC - **Alimera entered into a definitive merger agreement with ANI Pharmaceuticals Inc. on June 21, 2024**, valuing Alimera's equity at approximately **$320 million upfront**, with an expected closing later this year[3](index=3&type=chunk) - The company modified royalty payment terms with SWK Funding LLC, reducing the royalty rate to **3.125% of net revenues** for products containing fluocinolone acetonide (FAc), including ILUVIEN and YUTIQ[3](index=3&type=chunk) Detailed Financial Performance [Net Revenue](index=2&type=section&id=Net%20Revenue) Consolidated global net revenue increased significantly, driven by the acquisition of YUTIQ in the U.S. and strong sales volumes internationally, with both segments showing robust growth in Q2 2024 [Consolidated Global Net Revenue](index=2&type=section&id=Consolidated%20Global%20Net%20Revenue) Consolidated global net revenue for Q2 2024 was $27 million, a 54% increase from $17.5 million in Q2 2023, primarily due to the addition of YUTIQ in the U.S. and increased international sales | Metric | Q2 2024 (Millions) | Q2 2023 (Millions) | Change (YoY) | | :----------------------- | :----------------- | :----------------- | :----------- | | Consolidated Net Revenue | $27.0 | $17.5 | +54% | [U.S. Net Revenue](index=2&type=section&id=U.S.%20Net%20Revenue) U.S. net revenue grew 48% to $17.6 million in Q2 2024, up from $11.9 million in Q2 2023, largely attributed to the revenue generated by YUTIQ, acquired in May 2023. U.S. end user demand also increased by 6% | Metric | Q2 2024 (Millions) | Q2 2023 (Millions) | Change (YoY) | | :----------------------- | :----------------- | :----------------- | :----------- | | U.S. Net Revenue | $17.6 | $11.9 | +48% | | U.S. End User Demand | 2,189 units | N/A | +6% | - The increase in U.S. net revenue was primarily driven by net revenue from YUTIQ, which Alimera acquired in May 2023[4](index=4&type=chunk) [International Net Revenue](index=2&type=section&id=International%20Net%20Revenue) International net revenue surged by 65% to $9.4 million in Q2 2024, compared to $5.7 million in Q2 2023, fueled by increased stocking by international distributors and growth in end user demand, which also rose by 6% | Metric | Q2 2024 (Millions) | Q2 2023 (Millions) | Change (YoY) | | :----------------------- | :----------------- | :----------------- | :----------- | | International Net Revenue| $9.4 | $5.7 | +65% | | International End User Demand| 1,632 units | N/A | +6% | - The increase in international net revenue was driven by both increased stocking of international distributors and growth in end user demand[4](index=4&type=chunk) [Operating Expenses](index=2&type=section&id=Operating%20Expenses) Total operating expenses increased to $23.2 million in Q2 2024, up from $16.3 million in Q2 2023, primarily due to merger-related general and administrative expenses, expanded sales and marketing infrastructure, increased amortization from the YUTIQ acquisition, and higher stock-based compensation | Metric | Q2 2024 (Millions) | Q2 2023 (Millions) | Change (YoY) | | :----------------------- | :----------------- | :----------------- | :----------- | | Total Operating Expenses | $23.2 | $16.3 | +42.3% | - Key drivers for the increase in operating expenses include: **$2.2 million** in G&A expenses related to the ANI merger, **$1.8 million** in additional sales and marketing expenses for U.S. product expansion, **$1.2 million** in additional amortization from the YUTIQ acquisition, and **$1.2 million** in additional stock-based compensation[5](index=5&type=chunk) [Cash and Cash Equivalents](index=2&type=section&id=Cash%20and%20Cash%20Equivalents) Alimera's cash and cash equivalents decreased to $10.8 million as of June 30, 2024, from $14.3 million at March 31, 2024, primarily due to accrued licensor payments for YUTIQ and exit fee payments related to loan agreements | Metric | June 30, 2024 (Millions) | March 31, 2024 (Millions) | December 31, 2023 (Millions) | | :----------------------- | :----------------------- | :------------------------ | :--------------------------- | | Cash and Cash Equivalents| $10.8 | $14.3 | $12.1 | - During Q2 2024, the company made **$1.9 million** in accrued licensor payments for YUTIQ and **$2.4 million** in accrued exit fee payments due to revenue milestones[6](index=6&type=chunk) Company Information [About Alimera Sciences, Inc.](index=2&type=section&id=About%20Alimera%20Sciences%2C%20Inc.) Alimera Sciences is a global pharmaceutical company dedicated to retinal health, aiming to provide invaluable solutions for patients, physicians, and partners to maintain better vision longer - Alimera Sciences is a global pharmaceutical company focused on retinal health, with a mission to be invaluable to patients, physicians, and partners in maintaining better vision longer[7](index=7&type=chunk) Non-GAAP Financial Measures [Definition and Rationale](index=2&type=section&id=Definition%20and%20Rationale) Alimera uses Adjusted EBITDA as a non-GAAP financial measure to supplement GAAP results, believing it provides management and investors with a clearer understanding of ongoing operations and financial performance by excluding certain non-recurring or non-operational items - Alimera defines "Adjusted EBITDA" as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, gains on extinguishment of debt, preferred stock dividends, severance expenses, expenses incurred with Merger Agreement, and change in fair value of warrant asset[8](index=8&type=chunk) - The company uses Adjusted EBITDA to supplement GAAP financial information, believing it helps management understand ongoing operations and provides meaningful supplemental information to investors by excluding items not indicative of its core business[8](index=8&type=chunk)[9](index=9&type=chunk) [Limitations](index=3&type=section&id=Limitations) The company acknowledges that Adjusted EBITDA may not be comparable to similarly titled measures from other companies and should not be considered in isolation from or as a substitute for GAAP measures, as it excludes significant GAAP-required elements and involves management judgments - Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies due to varying calculation methods[9](index=9&type=chunk) - The presentation of this non-GAAP measure is not intended to be considered in isolation from or as a substitute for GAAP financial performance measures and should be read only in conjunction with GAAP information[10](index=10&type=chunk) - A principal limitation is that it excludes significant elements required by GAAP to be recorded in financial statements and reflects management's judgments[11](index=11&type=chunk) Legal and Disclosures [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section contains forward-looking statements regarding Alimera's future expectations, business strategy, and financial position, which are subject to inherent risks and uncertainties detailed in SEC filings. Investors are cautioned not to rely on these statements as predictions of future events - The press release includes forward-looking statements concerning growth opportunities, product demand, business strategy, future operations, financial position, revenues, costs, prospects, plans, and objectives[12](index=12&type=chunk) - These statements are based on current expectations and involve inherent risks and uncertainties, including factors discussed in Alimera's SEC filings (10-K, 10-Q)[12](index=12&type=chunk) - Investors are cautioned not to rely on forward-looking statements as predictions of future events, and Alimera undertakes no obligation to publicly update or revise them, except as required by law[13](index=13&type=chunk) [Additional Information and Where to Find It](index=4&type=section&id=Additional%20Information%20and%20Where%20to%20Find%20It) Alimera intends to file a proxy statement regarding the merger with ANI, and investors are urged to review all relevant documents filed with the SEC for important information about the transaction. These materials will be available free of charge on the SEC's website and the companies' respective websites - Alimera intends to file a preliminary and definitive proxy statement with the SEC in connection with the merger, which will be delivered to stockholders[14](index=14&type=chunk) - Investors and security holders are urged to read the definitive proxy statement and other relevant documents carefully when they become available, as they will contain important information about the merger[14](index=14&type=chunk) - Materials filed by ANI and Alimera can be obtained free of charge at the SEC's website (www.sec.gov) and their respective company websites (www.anipharmaceuticals.com and www.alimerasciences.com)[14](index=14&type=chunk) Unaudited Consolidated Financial Statements [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2024, Alimera's total assets were $150.4 million, a slight decrease from $153.5 million at December 31, 2023. Total liabilities increased to $111.6 million, while total stockholders' equity decreased to $38.8 million | Metric (In thousands) | June 30, 2024 | December 31, 2023 | | :-------------------- | :------------ | :---------------- | | Total Assets | $150,377 | $153,524 | | Total Liabilities | $111,589 | $107,354 | | Total Stockholders' Equity| $38,788 | $46,170 | | Cash and Cash Equivalents| $10,828 | $12,058 | | Accounts Receivable, net| $37,079 | $34,545 | | Inventory | $3,455 | $1,879 | | Notes Payable, net | $69,731 | $64,489 | [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) For Q2 2024, Alimera reported net revenue of $27.0 million, leading to a gross profit of $23.2 million. The company significantly reduced its net loss to $(3.3) million compared to $(10.0) million in Q2 2023, and net loss per share improved to $(0.06) | Metric (In thousands) | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | | :-------------------- | :------------------------------- | :------------------------------- | | Net Revenue | $27,000 | $17,538 | | Gross Profit | $23,169 | $15,113 | | Total Operating Expenses| $23,246 | $16,321 | | Loss from Operations | $(77) | $(1,208) | | Net Loss | $(3,311) | $(10,029) | | Net Loss per Share | $(0.06) | $(1.32) | [Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA](index=7&type=section&id=Reconciliation%20of%20GAAP%20Net%20Loss%20to%20Non-GAAP%20Adjusted%20EBITDA) Alimera's Non-GAAP Adjusted EBITDA for Q2 2024 was $6.7 million, a substantial increase from $0.9 million in Q2 2023, reflecting adjustments for interest expense, merger-related expenses, depreciation, amortization, and stock-based compensation, among other items | Metric (In thousands) | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | | :-------------------- | :------------------------------- | :------------------------------- | | U.S. GAAP Net Loss | $(3,311) | $(10,029) | | Interest expense and other, net| $3,153 | $1,694 | | Expenses incurred with Merger Agreement| $2,226 | — | | Depreciation and amortization| $3,093 | $1,866 | | Stock-based compensation| $1,457 | $217 | | Non-GAAP Adjusted EBITDA| $6,714 | $875 |

Financial Performance - Net revenue for the three months ended March 31, 2024, was $23,011,000, an increase of 70% compared to $13,546,000 for the same period in 2023[14] - Gross profit for the same period was $19,658,000, up from $11,518,000, reflecting a gross margin improvement[14] - The net loss for the three months ended March 31, 2024, was $6,251,000, compared to a net loss of $4,968,000 for the same period in 2023, resulting in a net loss per share of $0.12[14] - The company reported a net cash used in operating activities of $566,000 for the three months ended March 31, 2024, an improvement from $2,209,000 in the same period of 2023[21] - The company reported a net loss before taxes of $6.283 million for the three months ended March 31, 2024[145] - The company reported a net loss of $6.3 million for the three months ended March 31, 2024, compared to a net loss of $5.0 million in 2023[201] Operating Expenses - Total operating expenses increased to $21,960,000 from $14,820,000, primarily driven by higher sales and marketing expenses, which rose to $9,082,000 from $5,804,000[14] - Operating expenses increased to $22.0 million for the three months ended March 31, 2024, compared to $14.8 million in 2023, reflecting a 48.5% rise[201] - Stock-based compensation expense for the first quarter of 2024 was $845,000, reflecting the company's investment in employee incentives[26] - Research, development and medical affairs expenses increased by $0.2 million, or 5%, to $4.4 million for the three months ended March 31, 2024, compared to approximately $4.2 million for the same period in 2023[207] Cash and Assets - Cash and cash equivalents at the end of the period were $14,346,000, an increase from $13,117,000 at the end of the same period in 2023[21] - Total current assets increased to $54,469,000 from $52,423,000, with accounts receivable remaining stable at $34,224,000[11] - The total accumulated deficit as of March 31, 2024, was $424.741 million, an increase from $402.081 million at the end of the previous quarter[34] - As of March 31, 2024, total inventory increased to $2.206 million from $1.879 million as of December 31, 2023, representing a 17.4% increase[76] Liabilities and Debt - Total liabilities rose to $111,832,000 from $107,354,000, with long-term liabilities increasing to $90,043,000 from $79,625,000[11] - The company issued $5,000,000 in debt during the period, contributing to a net cash provided by financing activities of $2,967,000[21] - The Company entered into a $40.0 million loan agreement with SLR Investment Corp. in January 2018, which was refinanced to $45.0 million in December 2019[96] - The Company amended the 2019 Loan Agreement multiple times, with the most recent amendment increasing the loan facility from $67.5 million to $72.5 million[100] Revenue Recognition and Sales - The Company recognizes revenue based on ASC 606, with revenue from product sales recorded at the transaction price upon customer control, typically at delivery[44] - The Company recognizes collaboration and license revenue from upfront payments and milestone payments upon achieving specified objectives[54] - The Company has entered into a Product Rights Agreement with EyePoint Pharmaceuticals for the commercialization of YUTIQ, expanding its product portfolio[32] - The company recognized sales of ILUVIEN to international distributors in multiple countries, including the Middle East and China, indicating ongoing market expansion efforts[31] Stock and Equity - The Company issued 43,617,114 shares of common stock following the Mandatory Conversion of Series B Convertible Preferred Stock on August 15, 2023[117] - The 2023 Equity Incentive Plan reserves 3,231,755 shares of common stock, with an annual increase of 6% of outstanding shares starting from the first anniversary of the plan[119] - The 2024 Equity Inducement Plan reserves 800,000 shares for equity awards, approved without stockholder approval[120] - The total unrecognized compensation cost related to non-vested stock options was $4.9 million as of March 31, 2024, expected to be recognized over 3.27 years[122] Tax and NOLs - The company recorded a tax benefit of $32,000 for the three months ended March 31, 2024, with federal NOL carry-forwards of approximately $146.8 million and state NOL carry-forwards of approximately $106.8 million as of December 31, 2023[135] - The company is evaluating the impact of Section 382 limitations on its NOL carry-forwards due to ownership changes in late 2015 and 2023[137] - The Company utilized $1.1 million of net operating loss carryforwards from its Irish subsidiary as of December 31, 2023, and expects the remaining carryforward to be fully realizable in the future[138] Product Development and Market Expansion - ILUVIEN and YUTIQ are the only approved therapies for DME and NIU-PS that provide continuous daily therapeutic levels of corticosteroids for up to three years, significantly reducing the recurrence of these conditions[1] - The NEW DAY Study aims to evaluate ILUVIEN as a baseline therapy for early DME, with 300 treatment-naïve patients enrolled across 42 sites in the U.S.[5] - The SYNCHRONICITY Study has enrolled 110 patient eyes to assess the efficacy of YUTIQ in chronic inflammation over a treatment period of 36 months[6] - The Company acquired exclusive commercialization rights to YUTIQ for the treatment of chronic NIU-PS in May 2023, expanding its product portfolio[158]

Financial Data and Key Metrics Changes - Consolidated global net revenue increased 70% year-over-year to $23 million in Q1 2024, driven by the acquisition of YUTIQ and growth in global end-user demand [9][18] - Adjusted EBITDA was $1.8 million in Q1 2024, compared to an adjusted EBITDA loss of $2.4 million in Q1 2023 [9][21] - Net loss was approximately $6.3 million in Q1 2024, compared to approximately $5 million in Q1 2023 [21] Business Line Data and Key Metrics Changes - U.S. net revenue increased 92% to approximately $14.6 million in Q1 2024, primarily due to the acquisition of YUTIQ [10][18] - International net revenue grew 42% to approximately $8.5 million in Q1 2024, driven by a 53% increase in end-user demand [12][19] Market Data and Key Metrics Changes - U.S. end-user demand for products was up 96% in Q1 2024, including the addition of YUTIQ, and 2% on a pro forma basis [10][18] - International total end-user demand increased 53% to 2,050 units compared to Q1 2023 [19] Company Strategy and Development Direction - The company aims to grow the utilization of ILUVIEN and YUTIQ in 2024 and beyond, with a focus on cross-selling opportunities [23] - The NICE guidance in the U.K. is expected to expand the potential user base for ILUVIEN, positively impacting utilization in the second half of 2024 [13][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $105 million in revenue and at least 20% adjusted EBITDA margins for the year [9][24] - The company anticipates revenue fluctuations due to seasonality, but remains optimistic about long-term growth prospects [10][21] Other Important Information - The company has increased its term loan agreement by $5 million to provide more operating flexibility [22] - The first patient has been randomized in a significant clinical trial evaluating treatment options for radiation retinopathy [16] Q&A Session Summary Question: Awareness of Product Indications - Management acknowledged that there is an awareness issue among physicians regarding the dual indications of their products and is implementing an education campaign [26][29] Question: Rebating Strategy - A non-clinical value program was implemented to provide value back to physician practices using ILUVIEN or YUTIQ more consistently, with expectations for a small impact in Q2 [30][31] Question: Financial Support for Protocol AL Trial - The company will contribute approximately $1.25 million over four to five years for the protocol AL trial [41] Question: Impact of NICE Recommendation - The NICE recommendation is expected to potentially double the market for available patients in the U.K., but the speed of adoption remains uncertain [45] Question: Sales and Marketing Expenses - The company expects sales and marketing expenses to normalize after one-time costs incurred in Q1 2024 [35][63] Question: Field Feedback on New Messaging - Initial feedback on the new messaging has been positive, with advocates recognizing the importance of early intervention [68]

Revenue Growth - Net revenue increased by 70% to $23 million in Q1 2024 compared to $13.5 million in Q1 2023[3] - U.S. net revenue rose by 92% to approximately $14.6 million in Q1 2024, driven by the acquisition of YUTIQ[6] - International net revenue increased by 42% to approximately $8.5 million in Q1 2024, supported by growth in end user demand and distributor restocking[6] Demand and Units Sold - Global end user demand grew by 23% year-over-year, totaling 4,028 units for the quarter[3] Financial Performance - Adjusted EBITDA for Q1 2024 was positive at $1.8 million, compared to an adjusted EBITDA loss of $(2.4) million in Q1 2023[3] - The company reported a net loss of $6.3 million in Q1 2024, compared to a net loss of $5.0 million in Q1 2023[3] - U.S. GAAP net loss for Q1 2024 was $6,251,000, compared to a net loss of $4,968,000 in Q1 2023[18] - Non-GAAP adjusted EBITDA for Q1 2024 was $1,804,000, an improvement from a loss of $2,395,000 in Q1 2023[18] Operating Expenses - Total operating expenses increased to approximately $22 million in Q1 2024, up from $14.8 million in Q1 2023, primarily due to higher sales and marketing expenses[7] - Interest expense and other for Q1 2024 amounted to $3,739,000, up from $1,667,000 in Q1 2023[18] - Depreciation and amortization expenses increased to $3,085,000 in Q1 2024, compared to $681,000 in Q1 2023[18] - Stock-based compensation for Q1 2024 was $845,000, significantly higher than $226,000 in Q1 2023[18] - Foreign currency exchange losses were $196,000 in Q1 2024, compared to $13,000 in Q1 2023[18] - Severance expenses recorded in Q1 2024 were $176,000, with no such expenses reported in Q1 2023[18] Cash Position - Cash and cash equivalents as of March 31, 2024, were approximately $14.3 million, an increase from $12.1 million at the end of 2023[7] Future Outlook - The company aims to achieve $105 million in revenue and at least 20% EBITDA margins for the full year 2024[2] - The National Institute for Health and Care Excellence (NICE) recommended access to ILUVIEN for chronic diabetic macular edema patients in the UK, potentially expanding the market[4] Tax and Fair Value Changes - Income tax benefit for Q1 2024 was $(32,000), with no income tax benefit reported in Q1 2023[18] - Change in fair value of warrant asset was $46,000 in Q1 2024, compared to $(14,000) in Q1 2023[18]

Financial Data and Key Metrics Changes - In Q4 2023, consolidated global net revenue grew 88% to $26.3 million compared to Q4 2022 [9] - For the full year 2023, net revenue increased 49% to $80.8 million compared to $54.1 million in 2022 [21] - Adjusted EBITDA in Q4 2023 was $5 million, a significant improvement from an adjusted EBITDA loss of $1.2 million in Q4 2022 [10] - For the full year 2023, adjusted EBITDA was $8.7 million compared to a loss of $7.9 million in 2022 [23] Business Line Data and Key Metrics Changes - US net revenue in Q4 2023 increased 104% to $19.2 million compared to $9.4 million in Q4 2022 [10] - For the full year 2023, US net revenue increased 66% to $56.7 million compared to $34.2 million in 2022 [21] - International net revenue in Q4 2023 grew 54% to $7.1 million compared to approximately $4.6 million in Q4 2022 [20] - For the full year 2023, international net revenue increased 21% to approximately $24 million compared to $19.9 million in 2022 [21] Market Data and Key Metrics Changes - US end-user demand for products was up 4.4% in Q4 2023 versus the prior year and 11% on a pro forma basis for the full year [10] - International segment end-user demand grew 16.7% in Q4 and 11.8% for the full year, driven by markets such as the UK, Portugal, Ireland, Spain, and France [12] Company Strategy and Development Direction - The company aims to leverage the acquisition of YUTIQ to increase utilization of both ILUVIEN and YUTIQ in the US market [7] - The strategy includes expanding the sales force and promoting both products to enhance physician engagement and treatment options [28] - The company anticipates achieving over $105 million in revenue with an adjusted EBITDA margin of 20% for 2024 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming supply issues and expects to meet end-user demand in Europe moving forward [12] - The company is optimistic about the potential impact of NICE's guidance on expanding the patient base for ILUVIEN in the UK and potentially in other markets [15] - Management highlighted the importance of upcoming clinical study results, particularly the NEW DAY and SYNCHRONICITY studies, in shaping future treatment paradigms [17][18] Other Important Information - The company completed enrollment in two Phase IV clinical studies, which are expected to provide impactful data [16] - Cash and cash equivalents as of December 31, 2023, were approximately $12.1 million, up from $5.3 million at the end of 2022 [24] - The company increased the size of its loan facility by an additional $5 million to enhance operational flexibility [25] Q&A Session Summary Question: What is the expected utilization crossover for ILUVIEN and YUTIQ? - Management aspires to increase the crossover utilization to over 50% in the next 12 months, acknowledging that not all specialists will use both products [32] Question: What is the competitive environment for DME and Uveitis? - Management noted increased competition from new entrants but believes there remains a significant patient population that requires corticosteroid treatment [35] Question: When can top-line data for the NEW DAY study be expected? - Top-line data is anticipated in early 2025, following the last patient visit in Q4 2024 [37] Question: What is the expected interest expense for 2024? - The typical run rate for interest expense is expected to be around $3.5 million quarterly, with additional contingent interest payments anticipated [41]

Company Overview - Alimera Sciences specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals, focusing on chronic retinal diseases that affect millions globally[14]. - The company is dependent on the commercial success of ILUVIEN and YUTIQ, as they currently do not have other products or candidates available for sale or in clinical development[115]. Product Development and Commercialization - The company internally developed ILUVIEN (0.19 mg) for diabetic macular edema (DME) and acquired exclusive rights to YUTIQ (0.18 mg) in May 2023 for chronic non-infectious uveitis affecting the posterior segment of the eye[15]. - ILUVIEN and YUTIQ provide continuous microdosing of fluocinolone acetonide for up to 36 months, allowing patients to maintain vision longer with fewer injections[21]. - Alimera aims to maximize the commercial success of ILUVIEN and YUTIQ in current markets and plans to complete the SYNCHRONICITY and NEW DAY studies to enhance physician utilization of these products[17][18]. - The company is pursuing regulatory approvals for ILUVIEN in additional countries, including China, where a distributor plans to seek approval for DME treatment[18]. - The company is actively evaluating opportunities for further clinical trials of ILUVIEN in treating other ophthalmic diseases such as Retinal Vein Occlusion (RVO) and Age-related Macular Degeneration (AMD)[63]. Financial Performance - In fiscal year 2023, the company reported revenues of $56.7 million in the U.S. and $24.0 million internationally, compared to $34.2 million and $19.9 million in 2022, respectively[72]. - The company has incurred a cumulative deficit of $418.5 million from inception through December 31, 2023, and has experienced operating losses each year since inception[136]. - GAAP net loss for December 2023 was $20,132 million, compared to a loss of $18,107 million in 2022[276]. - Non-GAAP adjusted EBITDA for December 2023 was $8,711 million, an improvement from a loss of $7,877 million in 2022[276]. Market and Competition - The company is facing competition from major pharmaceutical and biotechnology companies in the development and commercialization of ILUVIEN and YUTIQ[73]. - The company believes ILUVIEN is underutilized and should be used earlier in DME treatment to control the disease process and reduce edema recurrence[46]. - The company faces significant competition from larger pharmaceutical and biotechnology companies, which may impact the commercial success of ILUVIEN and YUTIQ[115]. Regulatory and Compliance - The commercialization and regulatory approval of pharmaceutical products like ILUVIEN and YUTIQ are subject to FDA and foreign regulatory requirements, with potential sanctions for non-compliance[141]. - The company is required to meet post-marketing safety surveillance requirements to continue marketing approved products, including reporting any adverse events to the FDA[91]. - Compliance with complex foreign and U.S. laws may increase operational costs and expose the company to fines and penalties, impacting financial performance[126]. Intellectual Property - The active pharmaceutical ingredient in ILUVIEN and YUTIQ, FAc, is not patent protected, allowing competitors to develop alternative formulations[82]. - The company relies on its ability to protect intellectual property, with the success of its products dependent on obtaining and maintaining patent protection, which is uncertain in the biotechnology and pharmaceutical fields[155]. - The company may face patent infringement claims that could lead to substantial litigation costs and divert resources, impacting its ability to commercialize current and future products[156]. Strategic Partnerships - Alimera's collaboration with EyePoint Pharmaceuticals includes a royalty structure of 6% on net revenues up to $75 million and 8% on revenues exceeding that amount, with a future offset reducing these rates temporarily[30]. - An upfront payment of $75 million was made to EyePoint for the exclusive rights to YUTIQ, with additional quarterly payments totaling $7.5 million planned for 2024[31]. - The company has granted an exclusive license to Ocumension for the development and commercialization of its 0.19 mg fluocinolone acetonide intravitreal injection in China, East Asia, and the Western Pacific[115]. Risks and Challenges - The company faces significant regulatory, economic, and legal barriers that could adversely affect its operations and financial position[117]. - Cybersecurity threats pose risks to the company’s information technology systems, potentially leading to data breaches and operational disruptions[119]. - The company may need additional capital to fund operations and support growth, with potential dilution of stockholder investment if raised through equity[133]. Human Resources - The company employs 159 individuals as of February 29, 2024, with 154 being full-time employees[108]. - The company may need to invest significantly in recruiting and retaining qualified personnel to support future growth and commercialization efforts[121]. Market Opportunities - The International Diabetes Federation estimated that the prevalence of diabetes worldwide increased to 537 million in 2021 and is expected to rise to 783 million by 2045[34]. - The CDC reports that around 97.6 million people have prediabetes, with less than 20% aware of their condition, indicating a significant market opportunity for diabetes-related treatments[35]. - The company is exploring substantial market opportunities in China and the Western Pacific under a license agreement with Ocumension, although regulatory challenges remain[125].